Development and validation of an LC-MS/MS method for the simultaneous determination of bedaquiline and rifabutin in human plasma

J Pharm Biomed Anal. 2019 Nov 30:176:112775. doi: 10.1016/j.jpba.2019.07.023. Epub 2019 Aug 16.

Abstract

This article describes the simultaneous determination of bedaquiline fumarate (TMC-207) and rifabutin in human plasma by stable isotope dilution tandem mass spectrometry. The methodology was developed for an investigation of potential drug-drug interactions of the two anti-tuberculosis drugs when given together to healthy human volunteers. Use of the two drugs in combination to treat disease caused by Mycobacterium tuberculosis is contemplated as the bacterium becomes resistant to many currently available drugs.

Keywords: 25-O-Desacetylrifabutin; Bedaquiline; Bedaquiline metabolite M2; Mycobacterium tuberculosis; Rifabutuin; Stable isotope dilution tandem mass spectrometry; TMC-207.

Publication types

  • Validation Study

MeSH terms

  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / blood*
  • Antitubercular Agents / pharmacokinetics
  • Chromatography, High Pressure Liquid / methods
  • Diarylquinolines / administration & dosage
  • Diarylquinolines / blood*
  • Diarylquinolines / pharmacokinetics
  • Drug Interactions
  • Drug Monitoring / methods*
  • Drug Therapy, Combination
  • Humans
  • Rifabutin / administration & dosage
  • Rifabutin / blood*
  • Rifabutin / pharmacokinetics
  • Tandem Mass Spectrometry / methods
  • Tuberculosis / drug therapy

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Rifabutin
  • bedaquiline